FIELD: medicine.
SUBSTANCE: dry powder inhaler contains 1-30 mg of the dry powder preparation containing a number of particles of powdered diketopiperasine or its pharmaceutically acceptable salts; an inspiration-actuated dry powder inhaler having an air flow resistance of 0.065-0.200 (√kPa)/litre a minute, and provided with a mouthpiece, a container configured to hold the powder, and relatively rigid air passages, and also to deliver the particles to the patient's pulmonary circulation for one inhalation. What is disclosed is the dry powder composition for an application in treating patients suffering from diabetes.
EFFECT: more stable characteristics of the powder delivery, ease of use, and eliminated patient's discomfort.
15 cl, 42 dwg, 12 tbl
Title | Year | Author | Number |
---|---|---|---|
SYSTEMS AND METHODS FOR DRY POWDER DRUG DELIVERY | 2011 |
|
RU2571331C1 |
DRY POWDER DRUG DELIVERY SYSTEMS AND METHODS | 2013 |
|
RU2650035C2 |
INHALER FOR DRY POWDER AND SYSTEM FOR DRUG DELIVERY | 2016 |
|
RU2731107C2 |
ADVANCED DRY POWDER DELIVERY SYSTEM | 2010 |
|
RU2487731C2 |
DRY POWDER INHALER AND DRUG DELIVERY SYSTEM | 2009 |
|
RU2468832C2 |
DRY POWDER INHALER AND DRUG DELIVERY SYSTEM | 2009 |
|
RU2608439C2 |
DIKETOPIPERAZIN MICROPARTICLES WITH PARTICULAR AMOUNT OF ISOMERS | 2010 |
|
RU2490026C1 |
DRY POWDER INHALATION SYSTEM | 2009 |
|
RU2491103C2 |
DIKETOPIPERAZINE MICROPARTICLES WITH PARTICULAR SPECIFIC SURFACE AREAS | 2010 |
|
RU2509555C2 |
METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
Authors
Dates
2014-10-20—Published
2011-06-21—Filed